Literature DB >> 3350034

The biodistribution and pharmacokinetics of meta-iodobenzylguanidine in childhood neuroblastoma.

L S Lashford1, J Moyes, R Ott, S Fielding, J Babich, S Mellors, I Gordon, K Evans, J T Kemshead.   

Abstract

MIBG is generating considerable interest for the treatment of neuroblastoma. This study has investigated the biological variation in handling of the compound in children with neuroblastoma. The biodistribution of the compound has been characterised in children undergoing tracer administrations of 123I and 131I-mIBG. Estimates of hepatic and whole body radiation dose delivery have been made. The results indicate substantial interpatient variation in hepatic dose delivery. This organ may be critical in some patients undergoing targeted radiotherapy with mIBG.

Entities:  

Mesh：

Substances：

Year:  1988        PMID： 3350034     DOI： 10.1007/bf02574771

Source DB:  PubMed          Journal:  Eur J Nucl Med        ISSN： 0340-6997


  3 in total

1.  Iodine-131 metaiodobenzylguanidine for the locating of suspected pheochromocytoma: experience in 400 cases.

Authors:  B Shapiro; J E Copp; J C Sisson; P L Eyre; J Wallis; W H Beierwaltes
Journal:  J Nucl Med       Date:  1985-06       Impact factor: 10.057

2.  Advanced neuroblastoma: improved response rate using a multiagent regimen (OPEC) including sequential cisplatin and VM-26.

Authors:  E A Shafford; D W Rogers; J Pritchard
Journal:  J Clin Oncol       Date:  1984-07       Impact factor: 44.544

3.  Radiopharmaceutical treatment of malignant pheochromocytoma.

Authors:  J C Sisson; B Shapiro; W H Beierwaltes; J V Glowniak; M Nakajo; T J Mangner; J E Carey; D P Swanson; J E Copp; W G Satterlee
Journal:  J Nucl Med       Date:  1984-02       Impact factor: 10.057
  3 in total
  12 in total

1.  Application of radiobiological dosimetry to radionuclide directed therapy.

Authors:  W T Millar
Journal:  Br J Cancer Suppl       Date:  1990-07

2.  Biodistribution and Dosimetry of 18F-Meta-Fluorobenzylguanidine: A First-in-Human PET/CT Imaging Study of Patients with Neuroendocrine Malignancies.

Authors:  Neeta Pandit-Taskar; Pat Zanzonico; Kevin D Staton; Jorge A Carrasquillo; Diane Reidy-Lagunes; Serge Lyashchenko; Eva Burnazi; Hanwen Zhang; Jason S Lewis; Ronald Blasberg; Steven M Larson; Wolfgang A Weber; Shakeel Modak
Journal:  J Nucl Med       Date:  2017-07-13       Impact factor: 10.057

3.  Different concentrations of various radiopharmaceuticals in the two main liver lobes: a preliminary study in clinical patients.

Authors:  Hans Jacobsson; Eduard Jonas; Per M Hellström; Stig A Larsson
Journal:  J Gastroenterol       Date:  2005-07       Impact factor: 7.527

Review 4.  Where are we with nuclear medicine in pediatrics?

Authors:  H R Nadel
Journal:  Eur J Nucl Med       Date:  1995-12

Review 5.  Radioiodinated metaiodobenzylguanidine: a review of its biodistribution and pharmacokinetics, drug interactions, cytotoxicity and dosimetry.

Authors:  A R Wafelman; C A Hoefnagel; R A Maes; J H Beijnen
Journal:  Eur J Nucl Med       Date:  1994-06

6.  Dosimetry of iodine 131 metaiodobenzylguanidine for treatment of resistant neuroblastoma: results of a UK study.

Authors:  S L Fielding; M A Flower; D Ackery; J T Kemshead; L S Lashford; I Lewis
Journal:  Eur J Nucl Med       Date:  1991

7.  Predictors of toxicity in treating patients with neuroblastoma by radiolabeled metaiodobenzylguanidine.

Authors:  J C Sisson; B Shapiro; R J Hutchinson; J E Carey; K R Zasadny; S A Zempel; D P Normolle
Journal:  Eur J Nucl Med       Date:  1994-01

Review 8.  Radiolabeled metaiodobenzylguanidine for the treatment of neuroblastoma.

Authors:  Steven G DuBois; Katherine K Matthay
Journal:  Nucl Med Biol       Date:  2008-08       Impact factor: 2.408

9.  Characterization of Meta-Iodobenzylguanidine (mIBG) Transport by Polyspecific Organic Cation Transporters: Implication for mIBG Therapy.

Authors:  Antonio J López Quiñones; David J Wagner; Joanne Wang
Journal:  Mol Pharmacol       Date:  2020-06-02       Impact factor: 4.436

10.  The distribution of alternative agents for targeted radiotherapy within human neuroblastoma spheroids.

Authors:  R J Mairs; W Angerson; M N Gaze; T Murray; J W Babich; R Reid; C McSharry
Journal:  Br J Cancer       Date:  1991-03       Impact factor: 7.640
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.